Andra AP fonden Increases Position in Edwards Lifesciences Corporation $EW

Andra AP fonden increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6,616.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,600 shares of the medical research company’s stock after purchasing an additional 79,400 shares during the period. Andra AP fonden’s holdings in Edwards Lifesciences were worth $6,268,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Banco Santander S.A. purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $309,000. DNB Asset Management AS boosted its stake in shares of Edwards Lifesciences by 2.3% in the third quarter. DNB Asset Management AS now owns 304,655 shares of the medical research company’s stock worth $23,693,000 after acquiring an additional 6,861 shares during the period. Choreo LLC boosted its stake in shares of Edwards Lifesciences by 7.7% in the third quarter. Choreo LLC now owns 17,848 shares of the medical research company’s stock worth $1,388,000 after acquiring an additional 1,269 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Edwards Lifesciences by 4.7% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,165,301 shares of the medical research company’s stock worth $90,625,000 after purchasing an additional 52,700 shares in the last quarter. Finally, Citizens Business Bank raised its stake in Edwards Lifesciences by 1.7% during the 3rd quarter. Citizens Business Bank now owns 30,476 shares of the medical research company’s stock valued at $2,370,000 after purchasing an additional 518 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $86.47 on Friday. The firm has a market capitalization of $50.22 billion, a PE ratio of 47.25, a PEG ratio of 2.26 and a beta of 0.94. The stock’s fifty day moving average is $82.74 and its 200 day moving average is $81.25. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the firm earned $0.59 EPS. The company’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. This represents a 53.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This trade represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 67,804 shares of company stock worth $5,711,242. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EW. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 12th. BTIG Research reiterated a “buy” rating and issued a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Finally, Wells Fargo & Company raised their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.